Skip to content
Head to head

Evotec vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: EVO · TAK

Updated 9 minutes ago

1-year performance, rebased to 100

EVO -55.4%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
EVOTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price1.3221.77
Change today-8.97%+1.68%
1-year return-54.5%+57.5%
Market cap$469.11M$69.76B
52-week range1.32 – 3.8713.92 – 22.07
Valuation
P/E (TTM)-2.38311.00
P/E percentile, own 5-yr range77th100th
P/B0.671.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.32-0.30
Net profit (TTM)$-113.01M$-970.94M
Revenue (TTM)$718.32M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+0.6%+6.7%
Gross margin10.3%65.8%
Operating margin-17.5%14.3%
Net margin-25.2%0.9%
Free cash flow (TTM)$-136.72M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership50.8%51.3%
Insider activity (12mo)0 buy / 0 sell19 buy / 31 sell
Short interest (% of float)0.0%0.1%
Analyst consensus100% buy (1)100% buy (1)
Analyst price target$5 (+279%)$50 (+132%)
StockVane view
StockVane Quant RatingE (5)C (90)
Company
Employees4,55347,029
Founded19981781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.